JP Morgan Cuts Abbott Laboratories (ABT) Price Target to $118
Key Points
- JP Morgan maintained its Overweight rating on Abbott Laboratories on October 22, 2026, adjusting its price target to $118.00 from $120.00.
- JP Morgan's $118 price target implies 15.29% upside from Abbott Laboratories's ($ABT) current $102.35 share price.
- Abbott Laboratories recently traded around $101.34, sitting below its analyst price targets and moving averages.
- Several major firms updated their outlooks on the healthcare company on October 22, 2026, alongside ongoing institutional and insider activity.
Get Abbott Laboratories text alerts
We text you when insiders, Congress, analysts or big funds move on $ABT.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Abbott Laboratories alert may contain errors. Disclosures
JP Morgan maintained its Overweight rating on Abbott Laboratories on October 22, 2026, while lowering its price target from $120.00 to $118.00. The research note from the firm comes as Wall Street reassesses valuations across the medical devices sector.
ABT
Abbott Laboratories
JP Morgan's Call on Abbott Laboratories
In its October 22, 2026 note, JP Morgan kept its Overweight rating intact while trimming the target by $2.00 from a previous level of $120.00. The stock closed at $102.11 on the day of the rating update. Even with the reduced target, the firm continues to view the company favorably compared to industry peers.
Other Institutional Activity in Abbott Laboratories
Capital International Investors reduced its holdings in the company by 2,842,222 shares, ending its report period with 34,654,113 shares valued at about $3,538,704,674.
Abbott Laboratories Stock Down 0.1%
Shares recently traded around $101.34 as of October 22, 2026, down about 0.8% from the event close. The stock trades below its 50-day moving average of $105.49 and under its 200-day moving average of $102.46. The market capitalization stands at roughly $173.92 billion, with a trailing P/E ratio of 37.36 and a forward P/E of 16.79.
$ABT price target
Abbott Laboratories daily closes and this analyst's $118 target. Not advice.
Recent Earnings
The company reported trailing twelve-month revenue of $46.58 billion and earnings of $2.69 per share. Profitability metrics include a net margin of 11.6% and a return on equity of 10.6%, accompanied by a year-over-year revenue growth rate of 13.0%.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
8 target cuts vs 0 raises.
-
EPS & revenue
EPS met estimates. Revenue beat estimates by 0.5%.
-
Profit surprise
EBITDA missed by 43 percent. Operating income missed by 19 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
8 target cuts.
-
Earnings quality
Gross margin up 3.7 points. Positive free cash flow.
Earnings Call Summary
Abbott completed its $2.4 billion acquisition of Exact Sciences on March 23 and is integrating the cancer diagnostics business into its portfolio. First quarter results came in slightly ahead, with sales of $11.2 billion, up 3.7 percent on a comparable basis, though the respiratory season was weaker than expected. The company is seeing early signs of volume recovery in Nutrition after price increases, expects Core Lab Diagnostics to accelerate, and is launching new cardiac devices like the Volt pulsed field ablation catheter and TactiFlex Duo. Management remains confident in second half acceleration but is being cautious on near term market conditions.
Guidance Abbott cut full year earnings guidance from $5.68 to $5.48 per share, reflecting $0.20 of dilution from the Exact Sciences acquisition. The company guided full year revenue growth of 6.5 percent to 7.5 percent on a comparable basis including Exact Sciences. For the second quarter, Abbott expects earnings of $1.25 to $1.31 per share. Management said they are being conservative on respiratory season assumptions and expect acceleration in the second half driven by Nutrition recovery, Core Lab Diagnostics growth, and Exact Sciences integration.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
Shareholders receive an annual dividend rate of $2.52 per share, giving the stock a dividend yield of 2.46% based on a payout ratio of 78.7%.
Insider Buying and Selling at Abbott Laboratories
Insider transactions included a purchase by Director John G. Stratton, who bought 2,000 shares on May 7, 2026, at an average price of $86.82 for a total value of $173,640. On the selling side, officer Louis H. Morrone sold 5,850 shares on August 11, 2026, at $109.83 for $642,506. Chief Executive Officer Robert B. Ford sold 398,832 shares on August 25, 2026, and officer John A. McCoy Jr. sold 27 shares on September 2, 2026, at $109.54 for $2,958.
Analysts Set New Price Targets
RBC Capital maintained an Outperform rating on October 22, 2026, cutting its target from $130.00 to $125.00. Wells Fargo maintained an Overweight rating on October 22, 2026, lifting its target from $112.00 to $119.00. TD Cowen maintained a Buy rating on October 22, 2026, reducing its target from $135.00 to $118.00. Baird maintained an Outperform rating on October 22, 2026, raising its target to $123.00 from $121.00. Across 26 analyst opinions, the stock carries a consensus recommendation of strong buy and a mean price target of $120.41.
About Abbott Laboratories
Abbott Laboratories operates globally in the healthcare sector, focusing on the discovery, development, manufacturing, and sale of medical products. Its operations span established pharmaceutical products, diagnostic tools, nutritional goods, and specialized medical devices.
Bottom Line
Investors will follow upcoming earnings reports and future analyst updates to see if shares approach the new price targets set by major financial institutions. No investment advice is implied by these ratings.
Related Filing Alerts
Source: JP Morgan's rating change on $ABT (Oct 22, 2026). Written by software, not financial advice. How we make alerts